Published in World J Gastroenterol on January 07, 2012
ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol (2015) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
The Cholangiopathies. Mayo Clin Proc (2015) 0.98
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Liver Transplantation for Patients with Cholestatic Liver Diseases. Viszeralmedizin (2015) 0.83
Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era. Langenbecks Arch Surg (2014) 0.83
HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation. World J Gastroenterol (2014) 0.77
The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 0.77
Gene silencing of 4-1BB by RNA interference inhibits acute rejection in rats with liver transplantation. Biomed Res Int (2013) 0.76
Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran. Gastroenterol Hepatol Bed Bench (2015) 0.76
Recurrence of autoimmune liver diseases after liver transplantation. World J Hepatol (2015) 0.75
Recurrence of primary sclerosing cholangitis after liver transplantation - The Hungarian experience. Interv Med Appl Sci (2014) 0.75
Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol (2017) 0.75
Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management. Clin Med Insights Gastroenterol (2016) 0.75
Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease. World J Gastroenterol (2015) 0.75
Outcomes of Liver Transplant Recipients With Autoimmune Liver Disease Using Long-Term Dual Immunosuppression Regimen Without Corticosteroid. Transplant Direct (2017) 0.75
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 6.98
Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 4.76
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut (1980) 4.09
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet (2008) 3.99
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 3.72
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Choledochoduodenostomy is a safe alternative to Roux-en-Y choledochojejunostomy for biliary reconstruction in liver transplantation. World J Surg (2009) 3.47
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology (1997) 3.22
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology (2003) 2.89
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
A surgical experience with five hundred thirty liver transplants in the rat. Surgery (1983) 2.48
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med (1997) 2.41
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl (2005) 2.21
Primary sclerosing cholangitis; review and report of six cases. AMA Arch Surg (1958) 2.03
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Endoscopic retrograde cholangiopancreatography using a single-balloon enteroscope in patients with altered Roux-en-Y anatomy. Endoscopy (2010) 1.99
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol (2002) 1.96
The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol (2008) 1.92
Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91
Double balloon enteroscopy for endoscopic retrograde cholangiopancreaticography after Roux-en-Y reconstruction: case series and review of the literature. Neth J Med (2008) 1.75
Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc (2006) 1.74
Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol (1987) 1.73
Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology (1991) 1.73
A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl (2009) 1.72
Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology (1991) 1.72
Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol (2006) 1.71
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol (2000) 1.70
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol (2000) 1.67
Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc (2001) 1.66
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology (1990) 1.59
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol (1998) 1.57
HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol (1982) 1.53
Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl (2005) 1.52
Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant (2006) 1.50
Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant (2006) 1.50
The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection. Transplantation (2000) 1.47
MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology (2001) 1.47
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology (2005) 1.45
The immunology of experimental liver transplantation in the rat. Immunology (1985) 1.45
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis (2007) 1.42
Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol (2002) 1.41
Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (1998) 1.41
Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant (2009) 1.39
Sclerosing cholangitis: a focus on secondary causes. Hepatology (2006) 1.37
The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation (1990) 1.37
Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol (2006) 1.36
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology (2001) 1.31
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology (1999) 1.26
Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation: a systematic review of the incidence, risk factors and outcome. Transpl Int (2010) 1.21
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2008) 1.19
Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl (2008) 1.19
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (1992) 1.19
Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation. J Clin Pathol (2009) 1.18
Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology (1996) 1.16
Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet (2002) 1.16
Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg (1997) 1.16
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology (1999) 1.14
Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet (2002) 1.13
Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant (2008) 1.13
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.12
Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis (2006) 1.11
Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology (1991) 1.10
Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation (1995) 1.09
Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy (2002) 1.07
Liver transplantation: the current situation. Semin Liver Dis (2009) 1.07
Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest (1992) 1.07
Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation (2000) 1.07
Update on primary sclerosing cholangitis. Dig Liver Dis (2010) 1.06
"Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology (2000) 1.06
Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology (2010) 1.05
Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology (1991) 1.04
Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun (1991) 1.04
Current views on rejection pathology in liver transplantation. Transpl Int (2010) 1.03
Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl (2006) 1.03
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol (2010) 1.02
Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology (2004) 1.01
Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol (1994) 1.00
Biliary disease after liver transplantation: the experience of the King Faisal Specialist Hospital and Research Center, Riyadh. J Gastroenterol Hepatol (2005) 1.00
Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol (2007) 0.98
Liver transplantation for sclerosing cholangitis. Hepatology (1995) 0.98
The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int (2008) 0.98
Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol (2004) 0.96
Hilar biliary strictures after liver transplantation: cholangiography and percutaneous treatment. Radiology (1990) 0.96
The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg (1992) 0.96
Late acute rejection after liver transplantation impacts patient survival. Clin Transplant (2008) 0.96
Terminology for hepatic allograft rejection. International Working Party. Hepatology (1995) 0.96
Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation (1998) 0.96
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet (2008) 3.99
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg (2013) 2.07
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology (2013) 1.83
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics (2010) 1.81
Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology (2008) 1.79
Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol (2009) 1.76
Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet (2010) 1.72
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Primary sclerosing cholangitis. Lancet (2013) 1.59
Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology (2011) 1.51
Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol (2013) 1.47
Use of and attitudes to a hospital information system by medical secretaries, nurses and physicians deprived of the paper-based medical record: a case report. BMC Med Inform Decis Mak (2004) 1.46
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology (2011) 1.43
Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. J Hepatol (2006) 1.42
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Effects of scanning and eliminating paper-based medical records on hospital physicians' clinical work practice. J Am Med Inform Assoc (2003) 1.29
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software. Nucleic Acids Res (2012) 1.13
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut (2012) 1.11
Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes. Hypertension (2014) 1.11
Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology (2013) 1.11
Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology (2011) 1.09
Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07
SNP discovery performance of two second-generation sequencing platforms in the NOD2 gene region. Hum Mutat (2010) 1.05
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol (2010) 1.02
The utility of genome-wide association studies in hepatology. Hepatology (2010) 1.02
Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo. Transpl Int (2008) 1.01
Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun (2013) 0.96
Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis. BMC Med Genet (2007) 0.93
Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl (2010) 0.87
Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis (2009) 0.86
Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol (2015) 0.86
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol (2012) 0.85
TGR5 sequence variation in primary sclerosing cholangitis. Dig Dis (2011) 0.85
Update on primary sclerosing cholangitis genetics. Curr Opin Gastroenterol (2014) 0.84
Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology (2015) 0.83
Genetics in PSC: what do the "risk genes" teach us? Clin Rev Allergy Immunol (2015) 0.83
Analyzing antigen recognition by Natural Killer T cells. Methods Mol Biol (2013) 0.83
Primary sclerosing cholangitis - the Norwegian experience. Scand J Gastroenterol (2015) 0.82
Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int (2014) 0.81
Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway--a population-based cohort study. Cancer Epidemiol (2014) 0.80
Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis. Scand J Gastroenterol (2012) 0.80
Genetics in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol (2011) 0.80
Investigation of cholangiocarcinoma associated NKG2D polymorphisms in colorectal carcinoma. Int J Cancer (2008) 0.79
Transplantation With Livers From Deceased Donors Older Than 75 Years. Transplantation (2015) 0.78
Genome-wide association studies--a summary for the clinical gastroenterologist. World J Gastroenterol (2009) 0.78
[Liver transplantation in Norway through 25 years]. Tidsskr Nor Laegeforen (2009) 0.77
Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature (2016) 0.77
Association to the Glypican-5 gene in multiple sclerosis. J Neuroimmunol (2010) 0.76
To MMP or not to MMP: a role for matrix metalloproteinase 3 in primary sclerosing cholangitis? Liver Int (2011) 0.75
Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation. Scand J Gastroenterol (2015) 0.75
Correction: Abundant Genetic Overlap between Blood Lipids and Immune-Mediated Diseases Indicates Shared Molecular Genetic Mechanisms. PLoS One (2015) 0.75
An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2008) 0.75
Genetic Risk and the Development of Autoimmune Liver Disease. Dig Dis (2015) 0.75
Genetics in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol (2012) 0.75
Establishment of a surgical bile duct injection technique giving direct access to the bile ducts for studies of the murine biliary tree. Am J Physiol Gastrointest Liver Physiol (2017) 0.75
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease. Inflamm Bowel Dis (2017) 0.75
HDAC2 expression and variable number of repeats in exon 1 of the HDAC2 gene in corticotroph adenomas. Clin Endocrinol (Oxf) (2010) 0.75
Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease. Dig Dis (2017) 0.75